Clinical Research
Copyright ©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2007; 13(45): 6003-6008
Published online Dec 7, 2007. doi: 10.3748/wjg.v13.i45.6003
Table 4 Distributions of NAT2-haplotypes in TB patients with and without adverse effect
Hepatotoxicity
Skin rash
Eosinophilia
HaplotypePresent(%)Absent(%)OR95% CIPPresent(%)Absent(%)OR95% CIPPresent(%)Absent(%)OR95% CIP
NAT2*416 (44.4)120 (73.2)0.2650.129-0.546< 0.00134 (68.0)102 (68.0)1.000.503-1.9871.00045 (66.2)91 (68.9)0.8800.472-1.6420.688
NAT2*6A14 (38.9)29 (17.7)3.5351.648-7.585 0.00112 (24.0)31 (20.7)1.220.570-2.6070.60915 (22.0)28 (21.2)1.0520.517-2.1380.889
NAT2*7B6 (16.7)15 (9.1)2.2350.818-6.104 0.1174 (8.0)17 (11.3)0.700.226-2.1700.5378 (11.8)13 (9.9)1.2270.482-3.1240.667
Total number361645015068132

  • Citation: Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura KI, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S, Tsukamoto K. NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13(45): 6003-6008
  • URL: https://www.wjgnet.com/1007-9327/full/v13/i45/6003.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v13.i45.6003